LEXEO Trademark

Trademark Overview


On Wednesday, October 4, 2023, a trademark application was filed for LEXEO with the United States Patent and Trademark Office. The USPTO has given the LEXEO trademark a serial number of 98209814. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, April 1, 2025. This trademark is owned by Lexeo Therapeutics, Inc.. The LEXEO trademark is filed in the Pharmaceutical Products category with the following description:

House mark for the following, namely, Pharmaceutical preparations for the treatment of cardiovascular diseases, disorders, and defects; Pharmaceutical preparations for the treatment of Friedreich's Ataxia; Pharmaceutical preparations for the treatment of arrhythmogenic cardiomyopathy; Pharmaceutical preparations for the treatment of hypertrophic cardiomyopathy; Pharmaceutical preparations for the treatment of central nervous system diseases, disorders, and defects; Pharmaceutical preparations for the treatment of Alzheimer's disease; Pharmaceutical preparations for the treatment of Batten disease; Pharmaceutical preparations for the treatment of genetic diseases, disorders, and defects; Pharmaceutical preparations for the treatment of monogenic diseases, disorders, and defects; Biologic gene therapy preparations for the treatment of diseases, disorders, and defects; Therapeutic agents for delivery of genetically engineered viruses to patients for targeting underlying causes of diseases...
lexeo

General Information


Serial Number98209814
Word MarkLEXEO
Filing DateWednesday, October 4, 2023
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, April 1, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 4, 2025

Trademark Statements


Goods and ServicesHouse mark for the following, namely, Pharmaceutical preparations for the treatment of cardiovascular diseases, disorders, and defects; Pharmaceutical preparations for the treatment of Friedreich's Ataxia; Pharmaceutical preparations for the treatment of arrhythmogenic cardiomyopathy; Pharmaceutical preparations for the treatment of hypertrophic cardiomyopathy; Pharmaceutical preparations for the treatment of central nervous system diseases, disorders, and defects; Pharmaceutical preparations for the treatment of Alzheimer's disease; Pharmaceutical preparations for the treatment of Batten disease; Pharmaceutical preparations for the treatment of genetic diseases, disorders, and defects; Pharmaceutical preparations for the treatment of monogenic diseases, disorders, and defects; Biologic gene therapy preparations for the treatment of diseases, disorders, and defects; Therapeutic agents for delivery of genetically engineered viruses to patients for targeting underlying causes of diseases, disorders, and defects for treatment therefor; Therapeutic agents for delivery of genetically engineered viruses to patients for treatment of diseases, disorders, and defects; Pharmaceutical preparations for the detection or diagnosis of cardiovascular diseases, disorders, and defects; Pharmaceutical preparations for the detection or diagnosis of Friedreich's Ataxia; Pharmaceutical preparations for the detection or diagnosis of arrhythmogenic cardiomyopathy; Pharmaceutical preparations for the detection or diagnosis of hypertrophic cardiomyopathy; Pharmaceutical preparations for the detection or diagnosis of central nervous system diseases, disorders, and defects; Pharmaceutical preparations for the detection or diagnosis of Alzheimer's disease; Pharmaceutical preparations for the detection or diagnosis of Batten disease; Pharmaceutical preparations for the detection or diagnosis of genetic diseases, disorders, and defects; Pharmaceutical preparations for the detection or diagnosis of monogenic diseases, disorders, and defects; Biologic gene therapy preparations for the detection or diagnosis of diseases, disorders, and defects; Therapeutic agents for delivery of genetically engineered viruses to patients for detection or diagnosis of underlying causes of diseases, disorders, and defects; Therapeutic agents for delivery of genetically engineered viruses to patients for detection or diagnosis of diseases, disorders, and defects

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, October 13, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameLexeo Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10010

Party NameLexeo Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10010

Trademark Events


Event DateEvent Description
Saturday, October 7, 2023NEW APPLICATION ENTERED
Friday, May 24, 2024ASSIGNED TO EXAMINER
Friday, May 31, 2024NON-FINAL ACTION E-MAILED
Friday, May 31, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, May 31, 2024NON-FINAL ACTION WRITTEN
Friday, October 13, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, August 28, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Wednesday, November 27, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, August 28, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Wednesday, November 27, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, November 29, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, January 15, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, January 15, 2025APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 15, 2025NON-FINAL ACTION E-MAILED
Wednesday, January 15, 2025NON-FINAL ACTION WRITTEN
Wednesday, January 29, 2025NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 4, 2025PUBLISHED FOR OPPOSITION
Tuesday, February 4, 2025OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 1, 2025NOA E-MAILED - SOU REQUIRED FROM APPLICANT